Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 36, n° 6
pages 924-931 (juin 1997)
Doi : 10.1016/S0190-9622(97)80274-5
accepted : 4 January 1997
Brief communication

p53 tumor suppressor gene protein expression in premalignant and malignant skin lesions of kidney transplant recipients
 

Gillian E. Gibson, MRCPI a, , Anthony O'Grady, BSC a, Elaine W. Kay, MRCPath b, Mary Leader, MRCPath b, Gillian M. Murphy, FRCPI a
a Department of Dermatology, Beaumont Hospital, Dublin, Ireland 
b Department of Hispathology, Beaumont Hospital, Dublin, Ireland 

*Reprint requests: Gillian E. Gibson, MRCPl, Department of Dermatology, Mayo Clinic, Rochester, MN 55905.
Abstract
Background:

Kidney transplant recipients have an increased incidence of skin cancer, the cause of which is likely multifactorial. Inactivation of the tumor suppressor gene p53 protein may be important. Chemoprophylaxis of skin cancer with retinoids is beneficial in these patients.

Objective:

Our purpose was to investigate the immunohistochemical expression of p53 protein in premalignant and malignant cutaneous lesions in kidney transplant recipients and the effect of low-dose etretinate on p53 expression.

Methods:

Paraffin sections were stained with the monoclonal antibody DO-7.

Results:

Immunoreactivity of p53 was observed in 59% of basal cell carcinomas and more than 60% of squamous cell carcinomas, Bowen's disease, dysplastic lesions, and viral warts. No demonstrable effect of etretinate on p53 expression could be determined.

Conclusion:

The high prevalence of p53 immunoreactivity in premalignant and malignant skin lesions of kidney transplant recipients supports a role for p53 protein in skin cancer. This could be caused by mutation of the p53 gene, inactivation, or failure of degradation of p53 protein.

The full text of this article is available in PDF format.

Top of the page

© 1997  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@